Get information of interest (e.g., endpoint) from long data frame of protocol- or result-related trial information as returned by dfTrials2Long. Parameters `valuename`, `wherename` and `wherevalue` are matched using Perl regular expressions and ignoring case.
Arguments
- df
A data frame (or tibble) with four columns (`_id`, `identifier`, `name`, `value`) as returned by dfTrials2Long
- valuename
A character string for the name of the field that holds the value of the variable of interest (e.g., a summary measure such as "endPoints.*tendencyValue.value")
- wherename
(optional) A character string to identify the variable of interest among those that repeatedly occur in a trial record (e.g., "endPoints.endPoint.title")
- wherevalue
(optional) A character string with the value of the variable identified by `wherename` (e.g., "response")
Value
A data frame (or tibble, if dplyr
is loaded)
that includes the values of interest, with columns
`_id`, `identifier`, `name`, `value` (and `where`, with the
contents of `wherevalue` found at `wherename`).
Contents of `value` are strings unless all its elements
are numbers. The `identifier` is generated by function
dfTrials2Long to identify matching elements, e.g. endpoint descriptions and measurements.
Examples
dbc <- nodbi::src_sqlite(
dbname = system.file("extdata", "demo.sqlite", package = "ctrdata"),
collection = "my_trials")
dfwide <- dbGetFieldsIntoDf(
fields = c(
## ctgov - typical results fields
# "clinical_results.baseline.analyzed_list.analyzed.count_list.count",
# "clinical_results.baseline.group_list.group",
# "clinical_results.baseline.analyzed_list.analyzed.units",
"clinical_results.outcome_list.outcome",
"study_design_info.allocation",
## euctr - typical results fields
# "trialInformation.fullTitle",
# "baselineCharacteristics.baselineReportingGroups.baselineReportingGroup",
# "trialChanges.hasGlobalInterruptions",
# "subjectAnalysisSets",
# "adverseEvents.seriousAdverseEvents.seriousAdverseEvent",
"endPoints.endPoint",
"subjectDisposition.recruitmentDetails"
), con = dbc)
#> clinical_results.outcome_list.outcome...
#>
#> .
#> .
#>
#> study_design_info.allocation...
#>
#> .
#>
#> endPoints.endPoint...
#>
#> .
#>
#> subjectDisposition.recruitmentDetails...
#>
#> .
dflong <- dfTrials2Long(df = dfwide)
#> clinical_results.outcome_list.outcome
#> study_design_info.allocation
#> endPoints.endPoint
#> subjectDisposition.recruitmentDetails
#>
#> .
#> .
#> .
#> .
#> .
#> .
#> .
#> .
#>
#> Total 24916 rows, 91 unique names of variables
## get values for the endpoint 'response'
dfName2Value(
df = dflong,
valuename = paste0(
"clinical_results.*measurement.value|",
"clinical_results.*outcome.measure.units|",
"endPoints.endPoint.*tendencyValue.value|",
"endPoints.endPoint.unit"
),
wherename = paste0(
"clinical_results.*outcome.measure.title|",
"endPoints.endPoint.title"),
wherevalue = "response")
#> Returning values for 17 out of 56 trials
#> _id identifier
#> 1 2012-003632-23-AT 1
#> 2 2012-003632-23-AT 1
#> 3 2012-003632-23-AT 2
#> 4 2012-003632-23-AT 6
#> 5 2012-003632-23-AT 6.1
#> 6 2012-003632-23-AT 6.2
#> 7 2012-003632-23-AT 6.3
#> 8 2012-003632-23-AT 6.4
#> 9 2012-003632-23-AT 6.5
#> 10 2012-003632-23-AT 8
#> 11 2012-003632-23-AT 8
#> 12 2012-003632-23-CZ 1
#> 13 2012-003632-23-CZ 1
#> 14 2012-003632-23-CZ 2
#> 15 2012-003632-23-CZ 6
#> 16 2012-003632-23-CZ 6.1
#> 17 2012-003632-23-CZ 6.2
#> 18 2012-003632-23-CZ 6.3
#> 19 2012-003632-23-CZ 6.4
#> 20 2012-003632-23-CZ 6.5
#> 21 2012-003632-23-CZ 8
#> 22 2012-003632-23-CZ 8
#> 23 2012-003632-23-DE 1
#> 24 2012-003632-23-DE 1
#> 25 2012-003632-23-DE 2
#> 26 2012-003632-23-DE 6
#> 27 2012-003632-23-DE 6.1
#> 28 2012-003632-23-DE 6.2
#> 29 2012-003632-23-DE 6.3
#> 30 2012-003632-23-DE 6.4
#> 31 2012-003632-23-DE 6.5
#> 32 2012-003632-23-DE 8
#> 33 2012-003632-23-DE 8
#> 34 2012-003632-23-ES 1
#> 35 2012-003632-23-ES 1
#> 36 2012-003632-23-ES 2
#> 37 2012-003632-23-ES 6
#> 38 2012-003632-23-ES 6.1
#> 39 2012-003632-23-ES 6.2
#> 40 2012-003632-23-ES 6.3
#> 41 2012-003632-23-ES 6.4
#> 42 2012-003632-23-ES 6.5
#> 43 2012-003632-23-ES 8
#> 44 2012-003632-23-ES 8
#> 45 2012-003632-23-GB 1
#> 46 2012-003632-23-GB 1
#> 47 2012-003632-23-GB 2
#> 48 2012-003632-23-GB 6
#> 49 2012-003632-23-GB 6.1
#> 50 2012-003632-23-GB 6.2
#> 51 2012-003632-23-GB 6.3
#> 52 2012-003632-23-GB 6.4
#> 53 2012-003632-23-GB 6.5
#> 54 2012-003632-23-GB 8
#> 55 2012-003632-23-GB 8
#> 56 2012-003632-23-IT 1
#> 57 2012-003632-23-IT 1
#> 58 2012-003632-23-IT 2
#> 59 2012-003632-23-IT 6
#> 60 2012-003632-23-IT 6.1
#> 61 2012-003632-23-IT 6.2
#> 62 2012-003632-23-IT 6.3
#> 63 2012-003632-23-IT 6.4
#> 64 2012-003632-23-IT 6.5
#> 65 2012-003632-23-IT 8
#> 66 2012-003632-23-IT 8
#> 67 2012-003632-23-SE 1
#> 68 2012-003632-23-SE 1
#> 69 2012-003632-23-SE 2
#> 70 2012-003632-23-SE 6
#> 71 2012-003632-23-SE 6.1
#> 72 2012-003632-23-SE 6.2
#> 73 2012-003632-23-SE 6.3
#> 74 2012-003632-23-SE 6.4
#> 75 2012-003632-23-SE 6.5
#> 76 2012-003632-23-SE 8
#> 77 2012-003632-23-SE 8
#> 78 2013-005512-10-DE 4
#> 79 2013-005512-10-DE 4.1
#> 80 2013-005512-10-DE 4.2
#> 81 2013-005512-10-DE 4.3
#> 82 2013-005512-10-DE 4.4
#> 83 2013-005512-10-DE 4.5
#> 84 2013-005512-10-DE 4.6
#> 85 2013-005512-10-DE 4.7
#> 86 2013-005512-10-DE 4.8
#> 87 2013-005512-10-DE 4.9
#> 88 2013-005512-10-DE 4.10
#> 89 2013-005512-10-DE 4.11
#> 90 2013-005512-10-DE 4.12
#> 91 2013-005512-10-DE 10
#> 92 2013-005512-10-DK 4
#> 93 2013-005512-10-DK 4.1
#> 94 2013-005512-10-DK 4.2
#> 95 2013-005512-10-DK 4.3
#> 96 2013-005512-10-DK 4.4
#> 97 2013-005512-10-DK 4.5
#> 98 2013-005512-10-DK 4.6
#> 99 2013-005512-10-DK 4.7
#> 100 2013-005512-10-DK 4.8
#> 101 2013-005512-10-DK 4.9
#> 102 2013-005512-10-DK 4.10
#> 103 2013-005512-10-DK 4.11
#> 104 2013-005512-10-DK 4.12
#> 105 2013-005512-10-DK 10
#> 106 2013-005512-10-ES 4
#> 107 2013-005512-10-ES 4.1
#> 108 2013-005512-10-ES 4.2
#> 109 2013-005512-10-ES 4.3
#> 110 2013-005512-10-ES 4.4
#> 111 2013-005512-10-ES 4.5
#> 112 2013-005512-10-ES 4.6
#> 113 2013-005512-10-ES 4.7
#> 114 2013-005512-10-ES 4.8
#> 115 2013-005512-10-ES 4.9
#> 116 2013-005512-10-ES 4.10
#> 117 2013-005512-10-ES 4.11
#> 118 2013-005512-10-ES 4.12
#> 119 2013-005512-10-ES 10
#> 120 2013-005512-10-FR 4
#> 121 2013-005512-10-FR 4.1
#> 122 2013-005512-10-FR 4.2
#> 123 2013-005512-10-FR 4.3
#> 124 2013-005512-10-FR 4.4
#> 125 2013-005512-10-FR 4.5
#> 126 2013-005512-10-FR 4.6
#> 127 2013-005512-10-FR 4.7
#> 128 2013-005512-10-FR 4.8
#> 129 2013-005512-10-FR 4.9
#> 130 2013-005512-10-FR 4.10
#> 131 2013-005512-10-FR 4.11
#> 132 2013-005512-10-FR 4.12
#> 133 2013-005512-10-FR 10
#> 134 2013-005512-10-GB 4
#> 135 2013-005512-10-GB 4.1
#> 136 2013-005512-10-GB 4.2
#> 137 2013-005512-10-GB 4.3
#> 138 2013-005512-10-GB 4.4
#> 139 2013-005512-10-GB 4.5
#> 140 2013-005512-10-GB 4.6
#> 141 2013-005512-10-GB 4.7
#> 142 2013-005512-10-GB 4.8
#> 143 2013-005512-10-GB 4.9
#> 144 2013-005512-10-GB 4.10
#> 145 2013-005512-10-GB 4.11
#> 146 2013-005512-10-GB 4.12
#> 147 2013-005512-10-GB 10
#> 148 2013-005512-10-IE 4
#> 149 2013-005512-10-IE 4.1
#> 150 2013-005512-10-IE 4.2
#> 151 2013-005512-10-IE 4.3
#> 152 2013-005512-10-IE 4.4
#> 153 2013-005512-10-IE 4.5
#> 154 2013-005512-10-IE 4.6
#> 155 2013-005512-10-IE 4.7
#> 156 2013-005512-10-IE 4.8
#> 157 2013-005512-10-IE 4.9
#> 158 2013-005512-10-IE 4.10
#> 159 2013-005512-10-IE 4.11
#> 160 2013-005512-10-IE 4.12
#> 161 2013-005512-10-IE 10
#> 162 2013-005512-10-IT 4
#> 163 2013-005512-10-IT 4.1
#> 164 2013-005512-10-IT 4.2
#> 165 2013-005512-10-IT 4.3
#> 166 2013-005512-10-IT 4.4
#> 167 2013-005512-10-IT 4.5
#> 168 2013-005512-10-IT 4.6
#> 169 2013-005512-10-IT 4.7
#> 170 2013-005512-10-IT 4.8
#> 171 2013-005512-10-IT 4.9
#> 172 2013-005512-10-IT 4.10
#> 173 2013-005512-10-IT 4.11
#> 174 2013-005512-10-IT 4.12
#> 175 2013-005512-10-IT 10
#> 176 2013-005512-10-NL 4
#> 177 2013-005512-10-NL 4.1
#> 178 2013-005512-10-NL 4.2
#> 179 2013-005512-10-NL 4.3
#> 180 2013-005512-10-NL 4.4
#> 181 2013-005512-10-NL 4.5
#> 182 2013-005512-10-NL 4.6
#> 183 2013-005512-10-NL 4.7
#> 184 2013-005512-10-NL 4.8
#> 185 2013-005512-10-NL 4.9
#> 186 2013-005512-10-NL 4.10
#> 187 2013-005512-10-NL 4.11
#> 188 2013-005512-10-NL 4.12
#> 189 2013-005512-10-NL 10
#> 190 2013-005512-10-PL 4
#> 191 2013-005512-10-PL 4.1
#> 192 2013-005512-10-PL 4.2
#> 193 2013-005512-10-PL 4.3
#> 194 2013-005512-10-PL 4.4
#> 195 2013-005512-10-PL 4.5
#> 196 2013-005512-10-PL 4.6
#> 197 2013-005512-10-PL 4.7
#> 198 2013-005512-10-PL 4.8
#> 199 2013-005512-10-PL 4.9
#> 200 2013-005512-10-PL 4.10
#> name
#> 1 endPoints.endPoint.unit
#> 2 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 3 endPoints.endPoint.unit
#> 4 endPoints.endPoint.unit
#> 5 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 6 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 7 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 8 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 9 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 10 endPoints.endPoint.unit
#> 11 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 12 endPoints.endPoint.unit
#> 13 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 14 endPoints.endPoint.unit
#> 15 endPoints.endPoint.unit
#> 16 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 17 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 18 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 19 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 20 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 21 endPoints.endPoint.unit
#> 22 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 23 endPoints.endPoint.unit
#> 24 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 25 endPoints.endPoint.unit
#> 26 endPoints.endPoint.unit
#> 27 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 28 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 29 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 30 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 31 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 32 endPoints.endPoint.unit
#> 33 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 34 endPoints.endPoint.unit
#> 35 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 36 endPoints.endPoint.unit
#> 37 endPoints.endPoint.unit
#> 38 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 39 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 40 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 41 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 42 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 43 endPoints.endPoint.unit
#> 44 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 45 endPoints.endPoint.unit
#> 46 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 47 endPoints.endPoint.unit
#> 48 endPoints.endPoint.unit
#> 49 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 50 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 51 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 52 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 53 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 54 endPoints.endPoint.unit
#> 55 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 56 endPoints.endPoint.unit
#> 57 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 58 endPoints.endPoint.unit
#> 59 endPoints.endPoint.unit
#> 60 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 61 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 62 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 63 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 64 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 65 endPoints.endPoint.unit
#> 66 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 67 endPoints.endPoint.unit
#> 68 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 69 endPoints.endPoint.unit
#> 70 endPoints.endPoint.unit
#> 71 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 72 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 73 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 74 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 75 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 76 endPoints.endPoint.unit
#> 77 endPoints.endPoint.subjectAnalysisSetReportingGroups.subjectAnalysisSetReportingGroup.tendencyValues.tendencyValue.value
#> 78 endPoints.endPoint.unit
#> 79 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 80 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 81 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 82 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 83 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 84 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 85 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 86 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 87 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 88 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 89 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 90 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 91 endPoints.endPoint.unit
#> 92 endPoints.endPoint.unit
#> 93 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 94 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 95 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 96 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 97 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 98 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 99 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 100 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 101 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 102 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 103 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 104 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 105 endPoints.endPoint.unit
#> 106 endPoints.endPoint.unit
#> 107 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 108 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 109 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 110 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 111 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 112 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 113 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 114 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 115 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 116 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 117 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 118 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 119 endPoints.endPoint.unit
#> 120 endPoints.endPoint.unit
#> 121 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 122 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 123 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 124 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 125 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 126 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 127 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 128 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 129 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 130 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 131 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 132 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 133 endPoints.endPoint.unit
#> 134 endPoints.endPoint.unit
#> 135 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 136 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 137 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 138 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 139 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 140 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 141 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 142 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 143 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 144 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 145 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 146 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 147 endPoints.endPoint.unit
#> 148 endPoints.endPoint.unit
#> 149 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 150 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 151 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 152 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 153 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 154 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 155 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 156 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 157 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 158 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 159 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 160 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 161 endPoints.endPoint.unit
#> 162 endPoints.endPoint.unit
#> 163 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 164 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 165 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 166 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 167 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 168 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 169 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 170 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 171 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 172 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 173 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 174 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 175 endPoints.endPoint.unit
#> 176 endPoints.endPoint.unit
#> 177 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 178 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 179 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 180 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 181 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 182 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 183 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 184 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 185 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 186 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 187 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 188 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 189 endPoints.endPoint.unit
#> 190 endPoints.endPoint.unit
#> 191 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 192 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 193 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 194 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 195 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 196 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 197 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 198 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 199 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> 200 endPoints.endPoint.armReportingGroups.armReportingGroup.tendencyValues.tendencyValue.value
#> value
#> 1 Days
#> 2 7.0
#> 3 At least 1 response (number)
#> 4 Overall Response Rate
#> 5 0.63
#> 6 0
#> 7 0.65
#> 8 0.59
#> 9 0.60
#> 10 Percentage of treatment time
#> 11 78.6
#> 12 Days
#> 13 7.0
#> 14 At least 1 response (number)
#> 15 Overall Response Rate
#> 16 0.63
#> 17 0
#> 18 0.65
#> 19 0.59
#> 20 0.60
#> 21 Percentage of treatment time
#> 22 78.6
#> 23 Days
#> 24 7.0
#> 25 At least 1 response (number)
#> 26 Overall Response Rate
#> 27 0.63
#> 28 0
#> 29 0.65
#> 30 0.59
#> 31 0.60
#> 32 Percentage of treatment time
#> 33 78.6
#> 34 Days
#> 35 7.0
#> 36 At least 1 response (number)
#> 37 Overall Response Rate
#> 38 0.63
#> 39 0
#> 40 0.65
#> 41 0.59
#> 42 0.60
#> 43 Percentage of treatment time
#> 44 78.6
#> 45 Days
#> 46 7.0
#> 47 At least 1 response (number)
#> 48 Overall Response Rate
#> 49 0.63
#> 50 0
#> 51 0.65
#> 52 0.59
#> 53 0.60
#> 54 Percentage of treatment time
#> 55 78.6
#> 56 Days
#> 57 7.0
#> 58 At least 1 response (number)
#> 59 Overall Response Rate
#> 60 0.63
#> 61 0
#> 62 0.65
#> 63 0.59
#> 64 0.60
#> 65 Percentage of treatment time
#> 66 78.6
#> 67 Days
#> 68 7.0
#> 69 At least 1 response (number)
#> 70 Overall Response Rate
#> 71 0.63
#> 72 0
#> 73 0.65
#> 74 0.59
#> 75 0.60
#> 76 Percentage of treatment time
#> 77 78.6
#> 78 responses to injections
#> 79 102
#> 80 16
#> 81 2
#> 82 118
#> 83 163
#> 84 27
#> 85 14
#> 86 89
#> 87 20
#> 88 14
#> 89 3
#> 90 11
#> 91 subjects
#> 92 responses to injections
#> 93 102
#> 94 16
#> 95 2
#> 96 118
#> 97 163
#> 98 27
#> 99 14
#> 100 89
#> 101 20
#> 102 14
#> 103 3
#> 104 11
#> 105 subjects
#> 106 responses to injections
#> 107 102
#> 108 16
#> 109 2
#> 110 118
#> 111 163
#> 112 27
#> 113 14
#> 114 89
#> 115 20
#> 116 14
#> 117 3
#> 118 11
#> 119 subjects
#> 120 responses to injections
#> 121 102
#> 122 16
#> 123 2
#> 124 118
#> 125 163
#> 126 27
#> 127 14
#> 128 89
#> 129 20
#> 130 14
#> 131 3
#> 132 11
#> 133 subjects
#> 134 responses to injections
#> 135 102
#> 136 16
#> 137 2
#> 138 118
#> 139 163
#> 140 27
#> 141 14
#> 142 89
#> 143 20
#> 144 14
#> 145 3
#> 146 11
#> 147 subjects
#> 148 responses to injections
#> 149 102
#> 150 16
#> 151 2
#> 152 118
#> 153 163
#> 154 27
#> 155 14
#> 156 89
#> 157 20
#> 158 14
#> 159 3
#> 160 11
#> 161 subjects
#> 162 responses to injections
#> 163 102
#> 164 16
#> 165 2
#> 166 118
#> 167 163
#> 168 27
#> 169 14
#> 170 89
#> 171 20
#> 172 14
#> 173 3
#> 174 11
#> 175 subjects
#> 176 responses to injections
#> 177 102
#> 178 16
#> 179 2
#> 180 118
#> 181 163
#> 182 27
#> 183 14
#> 184 89
#> 185 20
#> 186 14
#> 187 3
#> 188 11
#> 189 subjects
#> 190 responses to injections
#> 191 102
#> 192 16
#> 193 2
#> 194 118
#> 195 163
#> 196 27
#> 197 14
#> 198 89
#> 199 20
#> 200 14
#> where
#> 1 Time to Overall Response
#> 2 Time to Overall Response
#> 3 Durability of First Response
#> 4 Overall Response
#> 5 Overall Response
#> 6 Overall Response
#> 7 Overall Response
#> 8 Overall Response
#> 9 Overall Response
#> 10 Cumulative Duration of Response
#> 11 Cumulative Duration of Response
#> 12 Time to Overall Response
#> 13 Time to Overall Response
#> 14 Durability of First Response
#> 15 Overall Response
#> 16 Overall Response
#> 17 Overall Response
#> 18 Overall Response
#> 19 Overall Response
#> 20 Overall Response
#> 21 Cumulative Duration of Response
#> 22 Cumulative Duration of Response
#> 23 Time to Overall Response
#> 24 Time to Overall Response
#> 25 Durability of First Response
#> 26 Overall Response
#> 27 Overall Response
#> 28 Overall Response
#> 29 Overall Response
#> 30 Overall Response
#> 31 Overall Response
#> 32 Cumulative Duration of Response
#> 33 Cumulative Duration of Response
#> 34 Time to Overall Response
#> 35 Time to Overall Response
#> 36 Durability of First Response
#> 37 Overall Response
#> 38 Overall Response
#> 39 Overall Response
#> 40 Overall Response
#> 41 Overall Response
#> 42 Overall Response
#> 43 Cumulative Duration of Response
#> 44 Cumulative Duration of Response
#> 45 Time to Overall Response
#> 46 Time to Overall Response
#> 47 Durability of First Response
#> 48 Overall Response
#> 49 Overall Response
#> 50 Overall Response
#> 51 Overall Response
#> 52 Overall Response
#> 53 Overall Response
#> 54 Cumulative Duration of Response
#> 55 Cumulative Duration of Response
#> 56 Time to Overall Response
#> 57 Time to Overall Response
#> 58 Durability of First Response
#> 59 Overall Response
#> 60 Overall Response
#> 61 Overall Response
#> 62 Overall Response
#> 63 Overall Response
#> 64 Overall Response
#> 65 Cumulative Duration of Response
#> 66 Cumulative Duration of Response
#> 67 Time to Overall Response
#> 68 Time to Overall Response
#> 69 Durability of First Response
#> 70 Overall Response
#> 71 Overall Response
#> 72 Overall Response
#> 73 Overall Response
#> 74 Overall Response
#> 75 Overall Response
#> 76 Cumulative Duration of Response
#> 77 Cumulative Duration of Response
#> 78 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 79 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 80 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 81 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 82 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 83 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 84 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 85 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 86 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 87 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 88 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 89 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 90 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 91 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 92 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 93 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 94 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 95 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 96 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 97 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 98 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 99 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 100 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 101 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 102 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 103 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 104 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 105 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 106 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 107 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 108 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 109 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 110 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 111 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 112 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 113 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 114 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 115 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 116 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 117 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 118 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 119 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 120 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 121 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 122 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 123 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 124 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 125 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 126 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 127 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 128 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 129 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 130 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 131 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 132 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 133 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 134 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 135 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 136 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 137 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 138 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 139 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 140 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 141 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 142 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 143 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 144 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 145 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 146 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 147 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 148 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 149 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 150 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 151 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 152 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 153 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 154 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 155 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 156 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 157 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 158 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 159 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 160 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 161 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 162 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 163 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 164 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 165 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 166 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 167 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 168 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 169 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 170 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 171 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 172 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 173 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 174 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 175 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 176 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 177 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 178 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 179 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 180 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 181 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 182 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 183 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 184 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 185 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 186 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 187 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 188 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 189 Number of Subjects with Response to Immune Tolerance Induction (ITI)
#> 190 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 191 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 192 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 193 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 194 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 195 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 196 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 197 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 198 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 199 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> 200 Number of rFVIIIFc Injections with Excellent or Good, Moderate or None Treatment Response Assessed Using a 4-Point Scale
#> [ reached 'max' / getOption("max.print") -- omitted 17 rows ]